The ACE inhibitor-angioedema mechanism is fundamentally different from allergic urticaria/angioedema — it is bradykinin-mediated, not histamine-mediated. ACEi block the angiotensin-converting enzyme, which is also responsible for breaking down bradykinin. Accumulation of bradykinin causes vasodilation and increased vascular permeability, particularly in the face, lips, tongue, and upper airway. This is critically important because: (1) it does not respond to antihistamines (histamine is not involved); (2) it does not respond to corticosteroids; (3) the reaction can occur months to years after starting the ACEi (it is not a type I hypersensitivity reaction); (4) it can be fatal if the upper airway is involved. The management is: stop the ACEi permanently (switching to a different ACEi does not eliminate the risk — it is a class effect). ARBs have lower bradykinin-accumulation risk but are not zero (some patients with ACEi angioedema also develop angioedema on ARBs). In the acute setting: icatibant (a bradykinin B2 receptor antagonist) is the specific antidote and should be given in hospital for upper airway involvement. GPs who identify ACEi-induced angioedema must add ACEi as an absolute allergy in the patient record AND ensure no future prescriber can restart it.

The 'ordinary urticaria moves within 24 hours' rule is the single most important clinical distinction between simple urticaria and urticarial vasculitis. Normal urticarial wheals form and resolve within 24 hours — individual wheals change location as new ones form elsewhere. If a patient shows you a wheal and says 'this one has been in the same place for 3 days,' or if the weal is painful rather than itchy, or if it leaves a bruise when it fades — it is NOT ordinary urticaria. It is urticarial vasculitis until a skin biopsy proves otherwise. The clinical significance: urticarial vasculitis can be associated with serious systemic disease (SLE in ~5% of cases, hepatitis B/C, Sjögren's syndrome, hypocomplementaemic urticarial vasculitis syndrome — HUVS) and requires a different investigation and management pathway. A wheal that persists >24 hours should prompt: skin biopsy (GP can arrange this or refer dermatology), ANA, dsDNA, complement (C3, C4, CH50), ANCA, hepatitis B/C serology, cryoglobulins.

The anti-TPO antibody association with chronic spontaneous urticaria is an important clinical connection — approximately 25% of patients with CSU have elevated anti-thyroid peroxidase (anti-TPO) antibodies, suggesting an autoimmune basis. The practical significance: (1) CSU patients should have TFTs checked (hypothyroidism may co-exist); (2) the presence of anti-TPO antibodies does not directly cause urticaria through thyroid dysfunction — the autoimmunity reflects a general propensity to produce autoantibodies, including IgG antibodies to the high-affinity IgE receptor (FcεRI) on mast cells, which directly trigger degranulation without IgE involvement. This autoimmune mechanism explains why: antihistamines often provide only partial relief in autoimmune CSU; omalizumab (anti-IgE monoclonal antibody) works dramatically well in CSU (by reducing free IgE available to bind to mast cell receptors, and possibly by reducing the density of IgE receptors on mast cells); and thyroid hormone replacement in hypothyroid CSU patients can improve urticaria independent of thyroid status correction.

UAS7 (Urticaria Activity Score 7) is the validated outcome measure used in all CSU clinical trials and is recommended by BSACI (British Society for Allergy & Clinical Immunology) and EAACI for monitoring CSU treatment response in primary care. It takes approximately 2 minutes per week for the patient to complete (or they can use the Urticaria App — available on iOS and Android). Incorporating UAS7 at each CSU review provides an objective measure of disease activity, documents treatment response, and triggers appropriate step-up decisions. A UAS7 consistently above 15 despite standard antihistamine = step-up to double or quadruple dose antihistamine; above 15 on high-dose antihistamine = omalizumab referral (NICE-approved for this indication).

Omalizumab (Xolair) is a transformative treatment for chronic spontaneous urticaria that is NICE-approved (TA339, 2015) and represents one of the most significant advances in dermatology in the past decade — it is a humanised anti-IgE monoclonal antibody that binds free IgE, preventing it from binding to IgE receptors on mast cells and basophils. In CSU, omalizumab achieves complete symptom control (UAS7 = 0) in approximately 35–40% of patients and meaningful improvement in approximately 70%. It is administered as a 300 mg SC injection every 4 weeks. The NICE criteria: CSU inadequately controlled by high-dose non-sedating antihistamine (up to 4× the standard dose) in adults and adolescents ≥12 years. A course of 6 months is typically given (responding patients can discontinue and re-introduce if relapse occurs — approximately 50% remain in remission after stopping). Dermatology initiates omalizumab; GPs can administer the injections in shared care after specialist training.

The 4× antihistamine dose recommendation for CSU is evidence-based (Cochrane review confirms superiority over standard dose) but technically off-label for most antihistamines — BSACI and EAACI urticaria guidelines both recommend increasing to 4× the licensed dose before escalating to omalizumab. The clinical rationale: histamine H1 receptor occupancy by antihistamines follows dose-response kinetics, and some patients require higher receptor occupancy for symptom control. The practical prescribing: cetirizine 10 mg QDS (four times daily) is the most commonly used dose escalation — it is generally well-tolerated, non-sedating, and achieves near-complete H1 receptor occupancy. When prescribing above the licensed dose, document the indication and the evidence base in the clinical record. Inform the patient that this is a dose higher than the packaging states, and why this has been recommended. The fact that it is 'off-label' does not mean it is unsafe — it means the pharmaceutical manufacturer has not submitted the additional dose for licensing (typically for commercial reasons).

The C4 level as a screening test for hereditary angioedema is a practical point that can expedite diagnosis in primary care — C4 (complement component 4) is chronically low in hereditary angioedema (Types I and II) because the unregulated complement activation caused by C1 inhibitor deficiency continuously consumes C4. Unlike C3 (which may be normal or mildly reduced), C4 is persistently low in HAE — even between attacks. A normal C4 level essentially excludes HAE Types I and II. GPs who encounter a patient with recurrent angioedema (especially facial/laryngeal, without urticaria wheals, family history of similar episodes) should check: C4 + C3 + C1 inhibitor level and function. The absence of urticaria wheals accompanying the angioedema is the key clinical distinguishing feature from allergic angioedema — HAE causes angioedema without urticaria because it is bradykinin-mediated, not histamine-mediated. This also explains why HAE attacks are not relieved by antihistamines or steroids.

The two-EpiPen prescription rule is a RESUS UK, BSACI, and allergy society recommendation — every patient with a history of anaphylaxis should be prescribed and carry two adrenaline auto-injectors at all times. The reasons: (1) the first device may misfire (device failure rate approximately 5%); (2) the first dose may be insufficient (particularly in large adults or severe reactions — some patients need two doses); (3) the peak plasma adrenaline level after IM injection is reached in approximately 8 minutes and begins to fall by 20 minutes — in biphasic anaphylaxis (which occurs in 20% of anaphylaxis cases, with a second wave of symptoms 1–72 hours after the initial reaction) a second dose may be needed. GPs must not prescribe a single EpiPen — this is specifically identified as a prescribing quality issue by BSACI. Both auto-injectors should be of the same device type (both EpiPen or both Jext — do not mix, as the activation mechanisms differ slightly). A simple inhaler technique session is insufficient — the patient AND their family/carers must practice with a trainer pen (available from the manufacturer free of charge).

The biphasic anaphylaxis concept is important for patient safety counselling — approximately 20% of anaphylaxis cases have a biphasic reaction, where symptoms recur 1–72 hours after the initial reaction (most commonly 6–12 hours) without re-exposure to the trigger. This is the reason all patients treated for anaphylaxis should be observed in hospital for a minimum of 6 hours (or 12 hours if severe). GPs should counsel patients who have had anaphylaxis: 'The reaction can sometimes come back hours later. If you use your EpiPen and your symptoms improve, you still need to call 999 and go to hospital, because the reaction may return even after it appears to have settled.' Anaphylaxis treated with adrenaline in the community is ALWAYS followed by hospital observation — it is not safe to go home after using an EpiPen just because symptoms have improved.